Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes

Circulation Research
L BelardinelliS P Baker

Abstract

This study demonstrates quantification of A2A adenosine receptors (A2AAdoRs) in membranes prepared from porcine coronary arteries, porcine striatum, and PC12 cells. Radioligand binding assays were performed using the new selective A2AAdoR antagonist radioligand [3H]-5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo [4,3-epsilon]-1,2,4-triazolo[1,5-c)pyrimidine ([3H]SCH58261). Binding of the radioligand to membranes was rapid, reversible, and saturable. The densities of A2AAdoRs in membranes prepared from porcine coronary arteries, porcine striatum, and PC12 cells were 900 +/- 61, 892 +/- 35, and 959 +/- 76 fmol/mg protein, respectively. Equilibrium dissociation constants (Kd values) calculated from results of saturation binding assays were 2.19, 1.20, and 0.81 nmol/L, and Kd values calculated from results of association and dissociation assays were 2.42, 1.01, and 0.40 nmol/L for [3H]SCH58261 binding to membranes prepared from porcine coronary arteries, porcine striatum, and PC12 cells, respectively. The specific binding of [3H]SCH58261 as a percentage of total binding at a radioligand concentration equal to the Kd value was 65% to 90% in the three membrane preparations. The order of ligand potencies determined by assay of competi...Continue Reading

Citations

Jul 3, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Mayumi SakiTomoyuki Kanda
Oct 17, 1998·European Journal of Pharmacology·J W PhillisM H O'Regan
Dec 1, 2001·Pharmacology & Therapeutics·R Tabrizchi, S Bedi
Dec 28, 1999·Brain Research. Brain Research Reviews·J L Moreau, G Huber
Jul 29, 1998·Bioorganic & Medicinal Chemistry·S A Poulsen, R J Quinn
Oct 30, 2013·Journal of Medicinal Chemistry·Manuel de Lera RuizJunying Zheng
Jun 18, 1999·British Journal of Pharmacology·B K Kemp, T M Cocks
Feb 29, 2000·British Journal of Pharmacology·S GessiP A Borea
Apr 27, 2002·British Journal of Pharmacology·Katia VaraniPier Andrea Borea
Mar 21, 1998·Journal of Veterinary Pharmacology and Therapeutics·J Elliott, F E Brady
May 30, 1998·British Journal of Pharmacology·K VaraniP A Borea
Jun 1, 1997·British Journal of Pharmacology·S DionisottiB B Fredholm
Aug 28, 2012·The Journal of Pharmacology and Experimental Therapeutics·Stefano ToldoAntonio Abbate
Feb 15, 2000·Journal of Cardiovascular Pharmacology·A Z Arif HasanS J Mustafa
Jul 1, 1999·Clinical and Experimental Pharmacology & Physiology·M J Lew, S W Kao
Nov 25, 1997·Annals of the New York Academy of Sciences·E OnginiR Bertorelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.